放化疗前后检测非小细胞肺癌外周血HIF-1α、VEGF-C表达的临床意义探讨  

Clinical significance of serum hypoxia-inducible factor-1α and Vascular endothelial growth factor-C mRNA in non-small cell lung cancer before and after radiochemotherapy

作　　者：汤忠祝[1,2] 朱远[2] 胡小云[2] 朱红洲[2] 陈鹏程[2] 沈朋[1] 

机构地区：[1]浙江大学医学院附属第一医院化疗科,杭州市310003 [2]浙江省肿瘤医院放疗科,杭州市310022

出　　处：《中华全科医学》2015年第4期538-540,共3页Chinese Journal of General Practice

基　　金：浙江省医药卫生科学研究基金(2008B026)

摘　　要：目的探讨非小细胞肺癌(NSCLC)患者放化疗前后外周血HIF-1α、VEGF-C表达与临床病理因素及近远期疗效的关系。方法随机选择2006年6月—2009年6月期间浙江省肿瘤医院收治的NSCLC患者122例,使用RT-PCR方法检测放化疗前后外周血HIF-1α、VEGF-C含量,同时测定30例正常体检者外周血作为对照,分析放化疗前后HIF-1α、VEGF-C表达与病理因素及近远期疗效的关系。结果治疗后HIF-1α、VEGF-C阳性表达率(23.8%和32.0%)比治疗前(48.4%和59.0%)明显下降。HIF-1α、VEGF-C治疗前后阳性表达率与NSCLC临床分期均相关(治疗前χ2=4.315、9.516,治疗后χ2=5.119、4.794,P<0.05)。HIF-1α、VEGF-C阴性表达者预后好于阳性表达者(治疗前χ2=24.011、9.871,治疗后χ2=15.492、5.826,P<0.05)。经放化疗,VEGF-C从阳性转为阴性与未转阴性者生存时间比较,差异具有统计学意义(χ2=4.322,P=0.038)。结论 HIF-1α、VEGF-C表达阳性者临床分期较高,预后较差;经放化疗,VEGF-C从阳性转为阴性者预后较好。HIF-1α、VEGF-C有望成为NSCLC治疗新的分子靶标。Objective To explore the relationship between Serum hypoxia-inducible factor-1 α, vascular endothelial growth factor-C, pathological factors and the immediate and long-term curative effect in non-small cell lung cancer before and after radiochemotherapy. Methods Serum HIF-1α and VEGF-C mRNA were detected in 122 NSCLC patients before and after radiochemotherapy and 30 healthy persons as control by Real-time PCR assay. Results The positive expression rates of HIF-1α and VEGF-C were 48.4% and 59.0% respectively before radiochemotherapy and there were 23.8% and 32.0% respectively after radiochemotherapy. The positive expression rates of HIF-1 α（ χ^2 = 4.315 and 5.119, P 〈 0.05 ） and VEGF-C（ χ^2 =9. 516 and 4.794 ,P 〈0.05） before and after radiochemotherapy were correlated with clinical stage. Patients with negative expression of HIF-lct and VEGF-C had more survival benefit than positive ones （χ^2 = 24.011,9. 871 before radiochemotherapy, X2 = 15. 492,5. 826 after radiochemotherapy, P 〈 0. 05 ）. There was statistical Significance in survival of VEGF-C between positive expression turn to negative and positive ones before radiochemotherapy（ χ^2 = 4. 322, P = 0. 038 ）. Conclusion Patients with positive expression of HIF-1α and VEGF-C had advanced clinical stage and less survival benefit. Patients with positive expression of VEGF-C turned to negative before radiochemotherapy had more survival benefit. HIF-1 α and VEGF-C will became new targets in non-small cell lung cancer treatment.

关 键 词：非小细胞肺癌 HIF-1Α VEGF-C 

分 类 号：R734.2[医药卫生—肿瘤]